#Germany #FAMAR Group #Homburg #MiP Pharma

FAMAR Group Expands Operations in Europe

FAMAR Group, a prominent player in the European pharmaceutical contract development and manufacturing organization (CDMO) arena, has made headlines with its recent announcement regarding the acquisition of a sterile production facility located in Homburg, Germany. This strategic move signifies a pivotal point in FAMAR's ongoing journey towards growth and expansion in the pharmaceutical manufacturing sector.

On May 14, 2025, the company revealed that it had signed an agreement to purchase this cutting-edge facility from MiP Pharma. The Homburg site, renowned for its modernized infrastructure and world-class capabilities, will bolster FAMAR's existing operations and enhance its expertise in producing high-value dosage forms, including aseptic and lyophilized fill-finish products.

Facilities and Future Prospects

With this acquisition, FAMAR's portfolio now encompasses seven operational sites across Europe, significantly improving their capacity to deliver flexible, high-quality, and scalable production solutions tailored to the needs of their customers. The Homburg facility recently underwent considerable investments that have modernized its production capabilities, making it a prime asset for FAMAR's international network.

Konstantinos Rengis, CEO of FAMAR Group, expressed his enthusiasm regarding the acquisition, noting that the Homburg site is equipped with state-of-the-art sterile infrastructure and newly installed quality control and microbiology laboratories. He highlighted the experienced workforce at the facility as an invaluable asset, further solidifying FAMAR's commitment to delivering manufacturing services of the highest standards.

Rengis added, "This investment aligns with our strategy to grow in differentiated dosage forms and expand our capacity to support global customers with manufacturing services of the highest standards. We are proud to welcome the Homburg team to the FAMAR family and look forward to building a strong future together."

Approximately 100 skilled employees from the Homburg facility will transition to FAMAR's management, ensuring the retention of knowledge and the seamless continuity of operations within the newly acquired site. Furthermore, FAMAR intends to develop the facility into a multi-customer CDMO platform, which aligns with their ambition to lead in complex and premium pharmaceutical manufacturing.

Comments from MiP Pharma

Dr. Friedrich Sernetz, CEO of MiP Pharma, also weighed in, praising the strategic move as beneficial for both parties. He noted, "Thanks to the investments, the Homburg facility has become an attractive site for global pharmaceutical specialists. With FAMAR, we have found a buyer who will further develop the site, which secures jobs and lays the foundation for future growth. At the same time, we can focus on our core competency – the marketing of our medicines – and accelerate our growth."

Supporting FAMAR's Mission

Investment firm MidEuropa, known for its role in the healthcare sector, shared its pleasure in supporting FAMAR's mission as they continue to serve their global customer base in a broader and more flexible capacity. According to Matthew Strassberg, a partner and head of MidEuropa's Healthcare Sector Practice, the acquisition exemplifies the firm’s strong commitment to supporting FAMAR's expansion into value-added formulations and service offerings.

About FAMAR Group

FAMAR is a distinguished European provider of pharmaceutical and cosmetic manufacturing and development services with a remarkable legacy spanning 75 years. The company produces a diverse range of dosage forms, including sterile liquids, powders, and semi-solids, while creating substantial value for clients across various markets. Operating in Spain, Italy, and Greece, and employing over 1,850 individuals, FAMAR boasts a robust manufacturing network comprising six production facilities and two research and development centers. The company proudly supplies over 1,700 different products to over 80 international markets.

About MiP Pharma Group

MiP Pharma Group specializes in market prescription generics, predominantly focusing on antibiotics, over-the-counter medications, and medical devices. With a strong emphasis on the hospital sector and targeting specialized groups, MiP Pharma has earned a solid reputation. The company employs over 200 individuals and holds around 400 marketing authorizations, generating approximately 50 million euros in sales in the previous financial year. MiP Pharma became part of the portfolio of Berlin-based financial investor capiton AG in November 2020.

FAMAR’s recent acquisition undoubtedly marks a significant step forward in their ambition to solidify their position as a leader in the pharmaceutical manufacturing sector, opening new doors for innovation and growth in the coming years.